{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:34:48Z","timestamp":1784244888195,"version":"3.55.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Statins could reduce the synthesis of steroid hormones, thereby could cause adrenal insufficiency. We investigated this risk in a large nationwide database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a nested case-control study using a cohort of individuals affiliated to the French health insurance system in 2010, \u226518y and without adrenal insufficiency history. Each case had a first event of adrenal insufficiency between 2015 and 2017 and was matched to up to ten controls on age, sex, and prior treatment with corticosteroids. Statin exposure was measured over the five years preceding the index date, considering a six-month censoring lag-time. Association was estimated using a conditional logistic regression adjusted for confounders included in a disease risk score. Analyses were stratified on age, sex and corticosteroid history of use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>4 492 cases of adrenal insufficiency were compared with 44 798 controls (median age 66y, 58% women), of which 39% vs. 33% were exposed to statins, respectively. No association between statin use and adrenal insufficiency was found when adjusting the model for confounders (adjusted odds ratio 0.98; 95% confidence interval 0.90-1.05). These results were consistent regardless of the exposure definition and stratifications considered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Statin-related adrenal insufficiency risk, if any, seems to be very limited and does not compromise the benefit of statin treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1254221","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T08:10:38Z","timestamp":1695715838000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Statin treatment is not associated with an increased risk of adrenal insufficiency in real-world setting"],"prefix":"10.3389","volume":"14","author":[{"given":"Sandy","family":"Maumus-Robert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jarne-Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Duroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise","family":"Duranteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Bezin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.amjcard.2005.06.009","article-title":"Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition beyond low-density lipoprotein cholesterol","volume":"96","author":"Liao","year":"2005","journal-title":"Am J Cardiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"zwad212","DOI":"10.1093\/eurjpc\/zwad212","article-title":"The effect of statins on mortality and cardiovascular disease in primary care hypertensive patients without other cardiovascular disease or diabetes","volume":"27","author":"Andersson","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.05.016","article-title":"Trends in lipid-modifying agent use in 83 countries","volume":"328","author":"Blais","year":"2021","journal-title":"Atherosclerosis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.08.1626","article-title":"How do statins work","volume":"62","author":"Blaha","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s13063-020-04259-5","article-title":"Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial","volume":"21","author":"Bonnet","year":"2020","journal-title":"Trials"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac020","article-title":"Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications","volume":"118","author":"Ruscica","year":"2022","journal-title":"Cardiovasc Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrendo.2015.194","article-title":"The diabetogenic action of statins \u2014 mechanisms and clinical implications","volume":"12","author":"Betteridge","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B10","first-page":"1","article-title":"Steroidogenic enzymes","volume-title":"Endocrine Development","author":"Miller","year":"2008"},{"key":"B11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1055\/a-1099-9556","article-title":"Acute statin administration reduces levels of steroid hormone precursors","volume":"52","author":"London","year":"2020","journal-title":"Horm Metab Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.016759","article-title":"Statin use and adrenal aldosterone production in hypertensive and diabetic subjects","volume":"132","author":"Baudrand","year":"2015","journal-title":"Circulation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.5551\/jat.10.160","article-title":"Atorvastatin treatment does not affect gonadal and adrenal hormones in type 2 diabetes patients with mild to moderate hypercholesterolemia","volume":"10","author":"Santini","year":"2003","journal-title":"JAT"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/0962280208092347","article-title":"Use of disease risk scores in pharmacoepidemiologic studies","volume":"18","author":"Arbogast","year":"2009","journal-title":"Stat Methods Med Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac359","article-title":"The changing face of drug-induced adrenal insufficiency in the food and drug administration adverse event reporting system","volume":"107","author":"Raschi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1176","article-title":"Use of lipid-lowering drugs and the risk of cataract: A population-based nested case-control study","volume":"105","author":"Bezin","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-066192","article-title":"Risk of first ischaemic stroke and use of antidopaminergic antiemetics: nationwide case-time-control study","volume":"376","author":"B\u00e9nard-Laribi\u00e8re","year":"2022","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"n37","DOI":"10.1136\/bmj.n37","article-title":"Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study","volume":"372","author":"Weill","year":"2021","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12902-017-0208-0","article-title":"Clinical characteristics of adrenal crisis in adult population with and without predisposing chronic adrenal insufficiency: a retrospective cohort study","volume":"17","author":"Iwasaku","year":"2017","journal-title":"BMC Endocr Disord"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2019.04.001","article-title":"Impact of underlying chronic adrenal insufficiency on clinical course of hospitalized patients with adrenal crisis: A nationwide cohort study","volume":"64","author":"Iwasaku","year":"2019","journal-title":"Eur J Internal Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.2.137","article-title":"Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: A randomized controlled trial","volume":"281","author":"Stein","year":"1999","journal-title":"JAMA"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006401.pub5","article-title":"Statins for children with familial hypercholesterolemia. Cochrane Cystic Fibrosis and Genetic Disorders Group","volume":"2019","author":"Vuorio","year":"2019","journal-title":"Cochrane Database Sys Rev"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1254221\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T08:10:43Z","timestamp":1695715843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1254221\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":24,"alternative-id":["10.3389\/fendo.2023.1254221"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1254221","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"article-number":"1254221"}}